Lumira Capital

About The Fund

Lumira Capital is an established investment fund focusing on the health and life science sectors, with a rich history dating back to its origin in 1989 as MDS Capital Corp. The firm underwent rebranding in September 2007, changing its name to Lumira Capital to better reflect its expertise and concentration in the North American health and life science sector. They specialize in later-stage investments, preferring companies that are approaching commercialization, with a particular interest in biopharmaceutical and medical device companies. Lumira Capital invests in entities that already possess preliminary clinical proof of concept data, showing promise for future success. Their investments often range from $5 to 10 million initially, with a broad scope that has led them to participate in the development of over 40 diseases targeted treatments and the launch of more than 35 approved products. These endeavors have successfully resulted in over $75 billion in cumulative revenue from approved products and collectively treated over 5 million patients. The firm has been involved in raising over $6 billion of capital for their portfolio companies. With headquarters in Toronto and additional offices in Montral, Vancouver, and Boston, they position themselves as key players in the life sciences venture capital arena in Canada and the U.S. Their investment portfolio covers a variety of sectors within health and life science, including biotech, medical devices and hospital services, robotics, and oncology. They describe their impact in terms of not only financial returns to investors but also the positive health outcomes and advancements in care that result from their investments.